An experienced, passionate team with a proven track record in collaborative clinical development and commercialization of novel therapies. Our team is focused on delivering strategic solutions that better the lives of patients, eyecare professionals, and more. With expertise in ophthalmology and retinal diseases, we welcome the challenges of the future.

Our strategy is focused on developing multiple, complementary assets to treat a broad spectrum of retinal diseases. We intend to do this by studying avacincaptad pegol in autosomal recessive stargardt disease and by advancing the development of IC-500 our HtrA1 inhibitor. Having both avacincaptad pegol and IC-500 in our pipeline positions us to potentially provide treatments for patients with various types and stages of AMD, the leading cause of vision loss in the elderly. We are also developing novel gene therapy technology to treat orphan inherited retinal diseases (IRDs). IRDs can be caused by many different mutations of a single gene. Our strategy is to develop mutation independent treatment options to potentially treat the entire group of patients with
a particular IRD.